Login to Your Account

On the Rebound

Stem Cell Sector Gets a Healthy Shot in the Arm

By Peter Winter

Monday, June 4, 2012

After a relatively tough year for stem cell companies on the public markets, they finally had something to cheer about – a regulatory milestone that could pave the way for a number of future approvals of stem cell therapies currently in late-stage clinical trials. The breakthrough event was Health Canada's approval of Prochymal (remestemcel-L), Osiris Therapeutics Inc.'s allogeneic stem cell treatment for graft-vs.-host disease (GvHD) in children.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription